Review
Immunology
Boyuan Huang, Xuesong Li, Yuntao Li, Jin Zhang, Zhitao Zong, Hongbo Zhang
Summary: Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor in the central nervous system. Immunotherapy has shown promising results in the treatment of GBM, but future developments will require an integrated approach with various treatment modalities and specific targeted therapies for the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Tingting Zhang, Hengqi Liu, Fenghua Gao, Wenchen Gong, Yaoli Cui, Jin He, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Huilai Zhang, Xianhuo Wang
Summary: This study investigates the role of N6-methyladenosine (m6A) modification in the tumor microenvironment of follicular lymphoma (FL). The researchers found that the m6A score is associated with prognosis and biological behavior in FL patients, and can predict the response to immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Xiang-Xu Wang, Haiyan Cao, Yulong Zhai, Shi-Zhou Deng, Min Chao, Yaqin Hu, Yueyang Mou, Shaochun Guo, Wenjian Zhao, Chen Li, Yang Jiao, Guolian Xue, Liying Han, Hong-Mei Zhang, Liang Wang
Summary: This study found that different immune subtypes have a significant impact on the survival of glioma patients. Patients with a high immune response subtype had a shorter survival, and the immune microenvironment of these patients showed enhanced immune cell infiltration. Furthermore, 132 genes related to glioma immunity were identified, and the expression levels of seven core genes were significantly correlated with the prognosis of glioma patients. These findings could be used to stratify glioma patients based on immune subgroup analysis and guide clinical treatment regimens.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Filippo Birocchi, Melania Cusimano, Federico Rossari, Stefano Beretta, Paola M. Rancoita, Anna Ranghetti, Stefano Colombo, Barbara Costa, Peter Angel, Francesca Sanvito, Marcella Callea, Rossana Norata, Linda Chaabane, Tamara Canu, Antonello Spinelli, Marco Genua, Renato Ostuni, Ivan Merelli, Nadia Coltella, Luigi Naldini
Summary: In this study, the authors engineered hematopoietic stem cells ex vivo to release interferon-alpha (IFN-alpha) or interleukin-12 (IL-12) at the tumor site, and achieved effective and tolerable treatment for glioblastoma multiforme (GBM) by reprogramming the tumor immune microenvironment.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Oncology
Montserrat Lara-Velazquez, Jack M. Shireman, Eric J. Lehrer, Kelsey M. Bowman, Henry Ruiz-Garcia, Mitchell J. Paukner, Richard J. Chappell, Mahua Dey
Summary: Immunotherapy combined with standard of care chemo-radiotherapy following surgical resection for newly diagnosed GBM did not show significant improvement in 1-year overall survival or progression-free survival compared to standard care alone. The combination therapy did not lead to a statistically significant increase in severe adverse events grade 3 to 5.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
Aida Karachi, Farhad Dastmalchi, Saina Nazarian, Jianping Huang, Elias J. Sayour, Linchun Jin, Changlin Yang, Duane A. Mitchell, Maryam Rahman
Summary: Evading T cell surveillance is a key aspect of cancer development. Patients with solid tissue malignancies like glioblastoma often experience immune dysfunction, particularly in T cell function. Standard treatments can worsen T cell dysfunction, but strategies like adoptive T cell transfer, including CAR T cells, offer potential for reinvigorating immune responses against cancer. However, there are risks of depletion and dysfunction in these adoptively transferred T cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Chao Lin, Ning Wang, Chengyan Xu
Summary: Glioma is a solid tumor composed of both neoplastic and non-neoplastic components. Glioma-associated macrophages and microglia (GAMs) are crucial in regulating tumor growth, invasion, and recurrence in the glioma tumor microenvironment. This review provides an overview of the intricate relationship between GAMs and the glioma tumor microenvironment, as well as a summary of immunotherapies targeting GAMs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Nathaniel D. Anderson, Jack Birch, Theo Accogli, Ignacio Criado, Eleonora Khabirova, Conor Parks, Yvette Wood, Matthew D. Young, Tarryn Porter, Rachel Richardson, Sarah J. Albon, Bilyana Popova, Andre Lopes, Robert Wynn, Rachael Hough, Satyen H. Gohil, Martin Pule, Persis J. Amrolia, Sam Behjati, Sara Ghorashian
Summary: In this study, the persistence of CD19 CAR-T cells in children with R/R B-ALL was analyzed, revealing a specific gene signature associated with long-lived CAR-T cells. This signature was found to be present in both children and adults with persistent CD19 CAR-T cells, indicating its potential as a universal transcriptional signature.
Review
Oncology
Joni Wahyuhadi, Irwan Barlian Immadoel Haq, Muhammad Reza Arifianto, Bagus Sulistyono, Rizki Meizikri, Atika Rosada, Cita Rosita Sigit Prakoeswa, Rahadian Indarto Susilo
Summary: Active immunotherapy appears to have a positive impact on the survival rate of glioblastoma patients, although the results are not statistically significant. It may be a potential treatment option for glioblastoma in the future.
Article
Clinical Neurology
Maricruz Rivera, Evan D. Bander, Babacar Cisse
Summary: Glioblastoma is the most aggressive primary tumor of the central nervous system with poor prognosis. Understanding the immune system's effects on glioma growth, invasion, survival, and angiogenesis is crucial for immunotherapy target development. Current clinical trials are investigating various approaches targeting the tumor microenvironment, as well as using vaccines, oncolytic viruses, antibodies, and chimeric antigen receptor T cells for treating glioma cells.
WORLD NEUROSURGERY
(2021)
Article
Neurosciences
Manuela Silginer, Eleanna Papa, Emese Szabo, Flavio Vasella, Martin Pruschy, Christopher Stroh, Patrick Roth, Tobias Weiss, Michael Weller
Summary: The HGF/MET signaling pathway is involved in the resistance of glioblastoma to radiotherapy. Inhibition of MET does not affect glioma cell viability or response to irradiation in vitro. However, combination of MET inhibitor tepotinib with radiotherapy prolongs survival in mouse glioma models by suppressing pro-inflammatory mediators. Clinical evaluation of this combination strategy is warranted in newly diagnosed glioblastoma.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2023)
Article
Genetics & Heredity
Lie Chen, Biao Fu
Summary: Despite the lack of approved ICB medications for glioma, this study utilized bioinformatics to construct a prognostic model related to T cell depletion and investigated its impact on prognosis and immunotherapy response in glioma patients. The TEXScore developed in this study effectively assessed the clinical status and immunotherapy response of glioma patients.
FRONTIERS IN GENETICS
(2022)
Review
Immunology
Ahmad Bakur Mahmoud, Reham Ajina, Sarah Aref, Manar Darwish, May Alsayb, Mustafa Taher, Shaker A. AlSharif, Anwar M. Hashem, Almohanad A. Alkayyal
Summary: Glioblastoma multiforme (GBM) is a common and aggressive brain tumor, but current therapies have limited effectiveness. Immunotherapy shows promise as a potential treatment for GBM.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Tiarne van de Walle, Alessandra Vaccaro, Mohanraj Ramachandran, Ilkka Pietila, Magnus Essand, Anna Dimberg
Summary: Glioblastoma is an aggressive brain tumor with a low prevalence of tumor-reactive T cells, and recent data suggest that naive T cells may be activated within brain tumor-associated tertiary lymphoid structures. Promoting tertiary lymphoid structures could enhance priming of tumor antigen-targeted T cells and sensitize glioblastomas to cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Angeliki Datsi, Ruediger V. Sorg
Summary: Dendritic cell vaccination (DCV) is a promising immunotherapy for treating glioblastomas, with numerous trials showing potential but some controlled studies failing to detect a survival benefit. Further exploration is needed to fully understand the potential of this therapeutic approach.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Health Care Sciences & Services
Juliana N. Pfeil, Dimitris Rados, Rudi Roman, Natan Katz, Luciana N. Nunes, Alvaro Vigo, Erno Harzheim
Summary: The telemedicine programme RegulaSUS in the state of Rio Grande do Sul, Brazil, has been shown to effectively reduce referral-to-consultation time and decrease the number of waitlisted patients, enabling sicker patients to reach specialists faster.
JOURNAL OF TELEMEDICINE AND TELECARE
(2023)
Article
Dentistry, Oral Surgery & Medicine
Leticia Rodrigues-Oliveira, Elisa Kauark-Fontes, Carolina Guimaraes Bonfim Alves, Juliana Ono Tonaki, Luiz Alcino Gueiros, Karina Moutinho, Gustavo Nader Marta, Luciana Rodrigues Carvalho Barros, Alan Roger Santos-Silva, Thais Bianca Brandao, Ana Carolina Prado-Ribeiro
Summary: The study found that anxiety, depression, and distress levels in head and neck cancer patients undergoing radiotherapy did not increase during the COVID-19 pandemic. Patients were afraid of being infected by COVID-19, but still complied with their cancer treatment.
Article
Oncology
Guilherme Giovanini, Luciana R. C. Barros, Leonardo R. Gama, Tharcisio C. Tortelli, Alexandre F. Ramos
Summary: Gene editing technologies have made significant progress in epigenetic modulation for cancer treatment. Gene networks, complex systems capable of processing dynamic information, lose their functionality in diseased states. By modulating multiple gene expression processes, it is possible to reduce heterogeneity and enhance specific treatment responses. Mathematical models are used to analyze stochastic gene expression, and simulation scenarios demonstrate the effectiveness of the approach. This method has potential for developing epigenetic-targeting treatments.
Review
Oncology
Luciana Rodrigues Carvalho Barros, Samuel Campanelli Freitas Couto, Daniela da Silva Santurio, Emanuelle Arantes Paixao, Fernanda Cardoso, Viviane Jennifer da Silva, Paulo Klinger, Paula do Amaral Costa Ribeiro, Felipe Augusto Ros, Theo Gremen Mimary Oliveira, Eduardo Magalhaes Rego, Rodrigo Nalio Ramos, Vanderson Rocha
Summary: This systematic review provides a worldwide overview of clinical trials evaluating new CAR-T cell therapies against different types of cancers, detailing the latest trends in CAR-T cell development. It predicts the potential approval of CAR-T cell therapies against hematological and solid tumor malignancies in the near future. China and the USA are leading in clinical studies involving CAR-T, with CD19 and BCMA being the most targeted hematological antigens.
Article
Pharmacology & Pharmacy
Gabriela Alves Moreira, Monica Maria Magalhaes Caetano, Juliana Alves do Vale, Janine Cerqueira de Paiva, Victor Hugo Sousa Goncalves, Alisson Andrade Almeida, Lucas Viana Gomes Silva, Fernanda Rebellato Giordano Martim, Marcus Vinicius de Andrade Barros, Gabriela Rapozo Guimaraes, Leandro de Oliveira Santos, Ana Paula Martins de Souza, Mariana Machado-Neves, Robson Ricardo Teixeira, Abelardo Silva-Junior, Juliana Lopes Rangel Fietto, Mariana Boroni, Leandro Licursi de Oliveira, Gustavo Costa Bressan
Summary: Cancers have a strong relationship with immune cells in their microenvironment, and pharmacological strategies that stimulate the immune system to combat tumor cells show promise for better therapeutic efficacy. This study found that overexpression of SRPK1/2 in melanoma is associated with alterations in the immune system pathway. Treatment with the SRPK1/2 inhibitor SRPIN340 in mice bearing metastatic melanoma increased the presence of immune cells and enhanced immunological susceptibility. These findings suggest that SRPKs may play a role in tumor biology by modulating the immune response.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Tatiana Dandolini Saccon, Felippe Mousovich-Neto, Raissa Guimaraes Ludwig, Victor Corasolla Carregari, Ana Beatriz dos Anjos Souza, Amanda Stephane Cruz dos Passos, Matheus Cavalheiro Martini, Priscilla Paschoal Barbosa, Gabriela Fabiano de Souza, Stefanie Primon Muraro, Julia Forato, Mariene Ribeiro Amorim, Rafael Elias Marques, Flavio Protasio Veras, Ester Barreto, Tiago Tomazini Goncalves, Isadora Marques Paiva, Narayana P. B. Fazolini, Carolina Mie Kawagosi Onodera, Ronaldo Braganca Martins Junior, Paulo Henrique Cavalcanti de Araujo, Sabrina Setembre Batah, Rosa Maria Mendes Viana, Danilo Machado de Melo, Alexandre Todorovic Fabro, Eurico Arruda, Fernando Queiroz Cunha, Thiago Mattar Cunha, Marco Antonio M. Pretti, Bradley Joseph Smith, Henrique Marques-Souza, Thiago L. Knittel, Gabriel Palermo Ruiz, Gerson S. Profeta, Tereza Cristina Minto Fontes-Cal, Mariana Boroni, Marco Aurelio Ramirez Vinolo, Alessandro S. Farias, Pedro Manoel M. Moraes-Vieira, Joyce Maria Annichino Bizzacchi, Tambet Teesalu, Felipe David Mendonca Chaim, Everton Cazzo, Elinton Adami Chaim, Jose Luiz Proenca-Modena, Daniel Martins-de-Souza, Mariana Kiomy Osako, Luiz Osorio Leiria, Marcelo A. Mori
Summary: Visceral adiposity is a risk factor for severe COVID-19, and the degree of adipose tissue infection and cellular response to SARS-CoV-2 depend on the adipose tissue depot and viral lineage. Visceral fat cells are more susceptible to SARS-CoV-2 infection and show higher expression of pro-inflammatory cytokines. Cell death occurs to a similar degree regardless of cell origin or viral lineage.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Bruna Palma Matta, Renan Gomes, Daniel Mattos, Renata Olicio, Caroline Macedo Nascimento, Gerson Moura Ferreira, Ayslan Castro Brant, Mariana Boroni, Carolina Furtado, Valdirene Lima, Miguel Angelo Martins Moreira, Anna Claudia Evangelista dos Santos
Summary: This study estimated the prevalence of pathogenic germline variants in BRCA1, BRCA2, and TP53 genes in Brazilian patients suspected of hereditary breast/ovarian cancer syndrome (HBOC). The study found that 15.9% of the tested patients carried pathogenic variants, with TP53 c.1010G > A (p.Arg337His) being the most common mutation. The use of familial history of cancer was found to improve patient selection for genetic testing in settings with limited resources.
SCIENTIFIC REPORTS
(2022)
Article
Genetics & Heredity
Monica Maria Magalhaes Caetano, Gabriela Alves Moreira, Maria Romeria da Silva, Gabriela Rapozo Guimaraes, Leandro de Oliveira Santos, Amanda de Ambrosio Pacheco, Raoni Pais Siqueira, Flavia Carneiro Mendes, Eduardo De Almeida Marques Da Silva, Abelardo Silva Junior, Juliana Lopes Rangel Fietto, Angela Saito, Mariana Boroni, Gustavo Costa Bressan
Summary: This study found that the expression of SRPK2 is associated with poor prognosis in melanoma patients. Genetic targeting of SRPK2 reduced the proliferative and invasive capacity of melanoma cells, leading to slower tumor progression. These findings suggest different functional roles for SRPK1/2 in metastatic melanoma.
FRONTIERS IN GENETICS
(2022)
Meeting Abstract
Cardiac & Cardiovascular Systems
Oscar Moreno Loaiza, Narendra Vera Nunez, Ainhoa Rodriguez de Yurre Guirao, Leonardo Maciel, Humberto Muzzi, Dahienne Ferreira de Oliveira, Luan Pereira Diniz, Mario Costa Cruz, Leonardo Ribeiro Batista-Silva, Archimedes Barbosa Castro-Junior, Marco Antonio Prettie, Pedro Nic, Mariana Boroni, Martin Bonamino, Isalira Peroba Ramos, Joao Paulo do Vale Madeiro, Roberto Coury Pedrosa, Marcela Sorelli Carneiro-Ramos, Herculano da Silva Martinho, Ariel L. Escobar, Emiliano Medei
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2022)
Article
Multidisciplinary Sciences
Ariane F. Busso-Lopes, Leandro X. Neves, Guilherme A. Camara, Daniela C. Granato, Marco Antonio M. Pretti, Henry Heberle, Fabio M. S. Patroni, Jamile Sa, Sami Yokoo, Cesar Rivera, Romenia R. Domingues, Ana Gabriela C. Normando, Tatiane De Rossi, Barbara P. Mello, Nayane A. L. Galdino, Bianca A. Pauletti, Pammela A. Lacerda, Andre Afonso N. Rodrigues, Andre Luis M. Casarim, Reydson A. De Lima-Souza, Ingrid I. Damas, Fernanda Mariano, Kenneth J. Gollob, Tiago S. Medina, Nilva K. Cervigne, Ana Carolina Prado-Ribeiro, Thais Bianca Brandao, Luisa L. Villa, Miyuki Uno, Mariana Boroni, Luiz Paulo Kowalski, Wilfredo Alejandro Gonzalez-Arriagada, Adriana F. Paes Leme
Summary: This study provides insights into the biology and potential biomarkers associated with metastasis in head and neck cancer through proteomic characterization and machine learning analysis.
NATURE COMMUNICATIONS
(2022)
Article
Cell Biology
Cristhiane Favero Aguiar, Felipe Correa-da-Silva, Michelangelo Bauwelz Gonzatti, Monara Kaelle Angelim, Marco Antonio Pretti, Gustavo Gastao Davanzo, Bianca Gazieri Castelucci, Lauar Brito Monteiro, Gisele Castro, Joao Victor Virgilio-da-Silva, Guilherme Ribeiro, Vitor Jaccomo, Mirella C. Pereira Andrade, Webster Leonardo Costa, Victor Gambarini, Fernanda Fernandes Terra, Jose Carlos Alves-Filho, Niels Olsen Saraiva Camara, Mariana Boroni, Alexandre Castro Keller, Pedro M. Moraes-Vieira
Summary: This study reveals that splenic and hepatic iNKT cells rely on glycolytic metabolism, while adipose tissue iNKT cells have a distinctive immunometabolic profile involving AMPK. Deletion of the Pkm2 gene impairs the response and injury mitigation ability of splenic and hepatic iNKT cells, while AMPK deficiency affects the physiology and inflammation regulation ability of adipose tissue iNKT cells during obesity.
Article
Oncology
Emanuelle A. Paixao, Luciana R. C. Barros, Artur C. Fassoni, Regina C. Almeida
Summary: The study presents the first mathematical model to describe the multiphasic treatment response in CAR-T cell kinetics, considering the dynamics of CAR-T and tumor cells. The model provides insights into the diverse dynamics of CAR-T cells in different patients and hematological cancers, and suggests potential markers for therapy classification.
Article
Engineering, Multidisciplinary
Daniela Silva Santurio, Emanuelle A. Paixao, Luciana R. C. Barros, Regina C. Almeida, Artur C. Fassoni
Summary: Long-term follow-up studies have shown that chimeric antigen receptor (CAR)-T cell therapy has resulted in non-durable remissions in many patients. In this study, a mathematical model based on integral-partial differential equations was developed to investigate the mechanisms of antigen-mediated resistance and its impact on therapy outcomes. The model successfully captured the dynamics of tumor and CAR-T cells in hematological cancers, providing a deeper understanding of key factors underlying resistance to CAR-T cell immunotherapy.
APPLIED MATHEMATICAL MODELLING
(2024)
Proceedings Paper
Computer Science, Interdisciplinary Applications
Diogo Munaro Vieira, Alexandre Heine, Elvismary Molina de Armas, Cristovao Antunes de Lanna, Mariana Boroni, Sergio Lifschitz
Summary: This paper presents an architecture that meets the interactive requirements of users in Scientific Workflow Management Systems (SWfMS). It also showcases an application in cancer gene identification for drug design.
ADVANCES IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY, BSB 2022
(2022)
Meeting Abstract
Oncology
Thayana Barbosa, Ana Luiza Maciel, Caroline Poubel, Mariana Boroni, Marcela Mansur, Mariana Emerenciano
PEDIATRIC BLOOD & CANCER
(2022)